ProMIS Neurosciences’ candidate PMN310 can specifically target toxic clusters of soluble amyloid-beta protein, and be safely administered at high doses with reduced risk of characteristic Alzheimer’s brain changes or swelling, according to clinical data. PMN310 has the potential for greater therapeutic potency compared with other amyloid-beta-directed antibodies for treating Alzheimer's disease, the researchers said. The findings, "Selective targeting of HHQK conformational epitope in amyloid-beta oligomer species by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer's disease," will be presented as a scientific poster during the Keystone Symposia on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities, taking place June 16-20 at the Keystone Resort in Colorado. Alzheimer's is a progressive neurodegenerative disorder characterized by excessive deposits of amyloid-beta and Tau proteins in the brain. Abnormal (toxic) forms of amyloid-beta fragments aggregate into insoluble plaques, or clumps, between neurons, interfering with cellular communication and eventually leading to nerve cell death. These plaques have long been thought to be the main molecular feature of Alzheimer’s.